COMMUNIQUÉS West-GlobeNewswire

BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
19/08/2025
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”), a medical device [...]
Aptitude Development Expands Partnership with Counslr to Offer 24/7 Mental Health Support Across All Properties Nationwide
19/08/2025
Unlimited, 24/7 text-based mental health support available to student residents as demand for wellness amenities grows NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Counslr , a leading B2B mental health and wellness [...]
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
19/08/2025
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a [...]
COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
19/08/2025
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient [...]
Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC
19/08/2025
NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics , Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with myeloproliferative [...]
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
19/08/2025
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in [...]
SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
19/08/2025
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an [...]
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
19/08/2025
SPC-15’s intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified [...]
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
19/08/2025
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. ( [...]
Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O’Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
19/08/2025
Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & [...]
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
19/08/2025
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the [...]
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
19/08/2025
Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
Walking Alone at Night is the Greatest Safety Fear of Women Nationwide -- Almost Half Say Safety Concerns Limit Daily Activities LogicMark Poll Reveals
19/08/2025
More women turn to technology solutions, with 71% looking to discreet devices for safety LOUISVILLE, Ky., Aug. 19, 2025 (GLOBE NEWSWIRE) -- A comprehensive new national survey commissioned by LogicMark, Inc. (OTC: LGMK [...]
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
19/08/2025
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from [...]
Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July
19/08/2025
Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical [...]
Cannabix Technologies delivers Marijuana Breath Test Hardware to Omega Laboratories Inc.
19/08/2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has delivered multiple Cannabix [...]
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
19/08/2025
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE [...]
Tria Federal Promotes Murali Mallina to Chief Technology Officer
19/08/2025
ARLINGTON, Va., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tria Federal (Tria) has promoted Murali Mallina to be the company’s new Chief Technology Officer (CTO). As CTO, Mallina will lead Tria Labs, Tria’s technology innovation [...]
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
19/08/2025
90-day trial measuring change in general fatigue in chronic babesiosis patients Enrollment expected to commence Q4 2025 and to be completed by Q2 2026 Site has clinical expertise in infectious disease trials and access [...]

Pages